SAVA - Cassava Sciences down another 3% as SEC provides update on simufilam probe
2024-07-01 12:17:48 ET
More on Cassava Sciences
- All Eyes On Simufilam: Cassava Sciences' Make-Or-Break Moment
- Cassava Sciences plunges 40% after simufilam researcher indicted on fraud charges
- Cassava swings to Q1 profit as more patients finish simufilam phase 3 trials
- Seeking Alpha’s Quant Rating on Cassava Sciences
- Historical earnings data for Cassava Sciences